Condition (MeSH)
Stevens-Johnson Syndrome
ClinicalTrials.gov lists 40 trials for Stevens-Johnson Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
40 of the 40 trials are tagged with Stevens-Johnson Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Stevens-Johnson Syndrome trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access)
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 5 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Stevens-Johnson Syndrome trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 8 |
| Phase 2 | 2 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Phase 4 | 3 |
| Not applicable | 10 |
| Observational | 9 |
| Expanded access | 1 |
How many Stevens-Johnson Syndrome trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 3 |
| Available | 1 |
| Completed | 14 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Stevens-Johnson Syndrome? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (CP-6890,550) Tofacitinib | 2 |
| INFLIXIMAB | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Site specific standard of care comparison | 1 |
| cultivated oral mucosal epithelial sheet transplantation | 1 |
| Adipose derived stromal cells intravenously injected | 1 |
| NaCl 0.9% NS | 1 |
| Harmonized supportive care | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Stevens-Johnson Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Corneal transplant | 2 | 1 |
| Cystoid macular oedema | 2 | 1 |
| Intraocular pressure increased | 2 | 1 |
| Retinal detachment | 2 | 1 |
| Retinopathy proliferative | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Stevens-Johnson Syndrome? (49)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. | The Journal of investigative dermatology | 2022 | Yes |
| The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. | Clinical and experimental rheumatology | 2021 | Yes |
| Searching for the Culprit Drugs for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis from a Nationwide Claim Database in Korea. | The journal of allergy and clinical immunology. In practice | 2020 | Yes |
| Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. | Expert review of clinical immunology | 2020 | Yes |
| Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. | Genetics in medicine : official journal of the American College of Medical Genetics | 2019 | Yes |
Showing 5 of 49 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Stevens-Johnson syndrome | Point prevalence | Unknown | Europe | Not stated | Exact |
| Stevens-Johnson syndrome | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Stevens-Johnson syndrome | Point prevalence | Unknown | Europe | Not stated | Unspecified |
| Stevens-Johnson syndrome | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Stevens-Johnson syndrome | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Stevens-Johnson syndrome | 36426 | Exact | Orphadata Science knowledge files, Product 1 |
| Stevens-Johnson syndrome | 36426 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors and sub-conditions in mesh.